Table 1.
Clinical characteristics of the participants for targeted gene panel testing (n = 116)
| Female: Male | 54 (46.6): 62 (53.4) |
|---|---|
| Age of seizure onset (year) |
|
| <6 months | 71 (61.2) |
| 6 months to 1 year | 29 (25.0) |
| 1–2 years | 16 (13.8) |
| Developmental delay | |
| Normal development | 49 (42.2) |
| Mild | 9 (7.8) |
| Moderate | 3 (2.6) |
| Severe | 54 (46.6) |
| Unknown a | 1 (0.9) |
| Family history of epilepsy | 31 (26.7) |
| Electroclinical syndrome | |
| Dravet syndrome | 21 (18.1) |
| EOEE | 29 (25.0) |
| GEFSP | 9 (7.8) |
| BFNS | 4 (3.4) |
| BFIE | 13 (11.2) |
| Unclassified | 33 (28.4) |
The data are described as numbers (%).
Abbreviations: BFIE, benign familial infantile epilepsy; BFNS, benign familial neonatal seizure; EOEE, early‐onset epileptic encephalopathy; GEFSP, generalized epilepsy with febrile seizure plus.
a
One patient was not exactly evaluated for development due to follow‐up loss.